Dystrophic Epidermolysis Bullosa Clinical Trial
Official title:
An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa
Verified date | May 2012 |
Source | Healthpoint |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a pilot study designed to see if HP802-247, an investigational treatment with living human skin cells, helps to heal blisters or wounds in subjects with Dystrophic Epidermolysis Bullosa (DEB). The durability of the skin in healed wounds treated with HP802-247 will also be assessed.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years and older |
Eligibility |
Inclusion Criteria: - Written consent must be obtained from a parent or legally authorized representative. Assent will be obtained according to local requirements. - Subjects with a clinical diagnosis of DEB with recurring blisters, = 2 years of age at Screening. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments. - A parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits. - A parent or legally authorized representative must be able to follow instructions. - Have an open wound for = 72 hours that: - is still open and has not scabbed or crusted over - has no dermatologic disease and/or condition in the treatment area (other than DEB with recurring blisters), including active or recent infection (within 7 days) that may be exacerbated by treatment, require treatment with antibiotics / antifungals /antivirals, require a surgical intervention, or cause difficulty with examination - is = 4 cm² and = 48 cm2 in total area (open portion) - Females of childbearing potential (defined as post-menarcheal as documented in the medical history) may participate in the study if they meet all of the following conditions: - they are not breast feeding; - they have a negative urine pregnancy test at Week 1 Period 1; - they agree to undertake scheduled urine pregnancy tests at Week 1 for Periods 1, 2, & 3 and at study exit - they do not intend to become pregnant during the study; - they are using adequate birth control methods and they agree to continue using those methods for the duration of the study - A parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits (for minor subjects) - A parent or legally authorized representative must be able to follow instructions (for minor subjects) Exclusion Criteria: - Contraindications or hypersensitivity to the use of the test article, their components (e.g., aprotinin, fibrinogen), or substances used in the manufacture of the test article (e.g., penicillin, streptomycin, amphotericin B, bovine serum albumin). - Therapy with another investigational agent within thirty (30) days of the Screening Visit, or during the study. - Have uncontrolled intercurrent or chronic illness that, in the opinion of the Investigator, would limit compliance with study requirements, represents a potential safety risk, or require treatment with an excluded drug/treatment. - The Investigator or Medical Monitor may declare any subject ineligible for a valid medical reason. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Healthpoint |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to healing | Time to healing, defined as the number of days between wound onset (caregiver reported) and complete epithelialization (Investigator assessed). | 4 weeks | No |
Secondary | Wound pain as measured by faces pain scale | Change from baseline (i.e., Week 1 of each period) in wound pain for each visit (Weeks 2-5 of each treatment period)as assessed by the Faces Pain Scale (FPS) | 4 weeks for each of 3 treatment periods | No |
Secondary | Percent of change in wound area | Percent of change from baseline (i.e., Week 1 of each period) in the target wound area for each visit and Weeks 2-5 of each treatment period. | 4 weeks for each of 3 treatment periods | No |
Secondary | Persistence of healing | Persistence of healing as assessed by lack of blister/wound recurrence for healed wounds of each period (up to 40 weeks following enrollment) | 4 weeks for each of 3 treatment periods | No |
Secondary | Burning and stinging upon application | Burning and stinging upon application of HP802-247 or its Vehicle will be assessed at each visit of each period with the exception of the end of treatment visit (Weeks 1-4 of treatment period). Burning/stinging scale is a four point scale (i.e., none, mild, moderate, severe). |
4 weeks for each of 3 treatment periods | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03536143 -
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT04917887 -
Long-Term Follow-up Protocol
|
||
Completed |
NCT04917874 -
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT03578029 -
Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT03472287 -
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
|
Phase 1 | |
Recruiting |
NCT05157958 -
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT02178969 -
Short Term Observational Study in DEB Patients
|
||
Withdrawn |
NCT04214002 -
The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
|
||
Recruiting |
NCT04757727 -
Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
|
||
Withdrawn |
NCT01768026 -
Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa
|
N/A | |
Completed |
NCT01538862 -
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
|
N/A | |
Completed |
NCT03183934 -
A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial
|
||
Completed |
NCT02579369 -
Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02004600 -
Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB
|
N/A | |
Completed |
NCT04491604 -
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
|
Phase 3 | |
Not yet recruiting |
NCT05529134 -
Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04173650 -
MSC EVs in Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 |